On May 9, 2023, Michael McCormick gave notice of his resignation from the Board of Directors of Perspective Therapeutics, Inc., effective immediately. Following Mr. McCormick's resignation, effective as of June 1, 2023, the Board appointed Ms. Heidi Henson as a director of the Company to fill the vacant position on the Board and a member of the Audit (as Chairperson) and Compensation committees of the Board. Effective June 1, 2023, Mr. Rob Williamson, III, current Chair of the Audit Committee will resign as Chair and continue to serve as a member of the Audit Committee.

Also, effective June 1, 2023, Ms. Lori Woods current Chair of the Compensation Committee will resign as Chair and continue to serve as a member of the Compensation Committee and Mr. Williamson will serve as the Chair of the Compensation Committee. Heidi Henson, age 57, Chair of the Audit Committee – Heidi Henson is a financial professional with over 25 years of experience in both public and private companies. Prior to joining the Board, Ms. Henson served as the Chief Financial Officer of Pardes Biosciences, Inc. since 2021.

Prior to that, she was a financial consultant for the same company from 2020 to her appointment as Chief Financial Officer. From 2019 through 2020, she was the Chief Financial Officer of Imbria Pharmaceuticals, Inc. From 2018 through 2019, she was the Chief Financial Officer of Respivant Sciences, Inc. From 2014 through 2018, she was the Chief Financial Officers of Kura Oncology, Inc. From 2012 through 2018, Ms. Henson was the Chief Financial Officer for Wellspring Biosciences LLC and Araxes Pharma LLC (its parent company). Ms. Henson is currently serving on the board of directors of PepGen and Lista Therapeutics, Inc. Ms. Henson holds a Bachelor of Accountancy from the University of San Diego and is a member of the Association of Bioscience Financial Officers (ABFO).